David Shaywitz

Last year, at about this time, I shared my experience losing 80 pounds. I achieved this goal through a low-carb diet and coaching, guided by the Virta program, along with regular exercise. The overarching concern I expressed in that article, one year ago, was my recognition of how fragile weight loss can be. Most people who lose significant weight soon gain it... Read More

I listen to a lot of audio, spoken word content that edifies (or at least distracts) me during daily workouts and when traveling.  Traditionally in December, I like to share with readers my annual podcast recommendations. But in reflecting on my listening habits of the last year, I realized that I’ve probably spent at least as much time listening to... Read More

Biopharmaceutical and healthcare executives increasingly find themselves attending conferences and presentations featuring the evangelistic selling of AI by self-assured VCs, energetic entrepreneurs, and earnest consultants.  The promise is that AI will change everything. Then the executives return to work, face the quotidian reality of their operation, and wonder whether AI will change anything. Enter Jim Manzi. Manzi, depending on your view, is a... Read More

Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant... Read More

[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech... Read More